S-1: Aptevo Therapeutics Launches Public Offering Amidst Nasdaq Compliance Concerns and Promising Clinical Data

Aptevo Therapeutics Inc. has initiated a public offering of common stock and warrants to raise approximately $7.2 million, while simultaneously addressing significant financial challenges including a shareholders' deficit and Nasdaq listing non-compliance, despite reporting positive clinical trial results for its lead cancer candidates.

Summary

• Aptevo Therapeutics Inc. is conducting a 'reasonable best efforts' public offering of up to 1,709,401 shares of common stock, up to 1,709,401 pre-funded warrants, and up to 8,547,005 common warrants.
• The assumed combined public offering price is $4.68 per share or pre-funded warrant, with each share/pre-funded warrant offered alongside five common warrants.
• The company expects to raise approximately $7.2 million in net proceeds from this offering, excluding potential proceeds from the cash exercise of common warrants.
• Additional net proceeds could reach approximately $37.1 million if all common warrants are exercised in full for cash, or $8.0 million if exercised at the floor price of $0.936 per share.
• The proceeds are intended for working capital, general corporate purposes, and the further development of product candidates.
• Aptevo reported a net loss of $(6.408) million for the three months ended March 31, 2025, and a net loss of $(24.130) million for the year ended December 31, 2024.
• As of March 31, 2025, the company had a net tangible book liability of $(2.9) million, or $(40.33) per share, which is projected to become an as-adjusted net tangible book value of $4.2 million, or $2.37 per share, after the offering.
• The company's common stock outstanding as of June 9, 2025, was 755,856 shares, increasing to 2,465,257 shares immediately after the offering (assuming full exercise of pre-funded warrants).
• Aptevo is a clinical-stage biotechnology company focused on bispecific immunotherapy for cancer, utilizing its proprietary ADAPTIR and ADAPTIR-FLEX platforms.
• Its lead clinical candidate, mipletamig, is being evaluated in the RAINIER Phase 1b/2 trial for frontline acute myelogenous leukemia (AML), showing positive initial results with 5 of 6 evaluable patients achieving remission.
• Another clinical candidate, ALG.APV-527, developed with Alligator Bioscience AB, is being evaluated for solid tumors, with preliminary results showing 58% of 19 patients achieving stable disease and positive safety data (no liver toxicity).
• Preclinical candidates include APVO603, APVO442, and APVO711, with a provisional patent filed for APVO711 in January 2023 and amended in January 2024.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to severe financial distress, including a significant shareholders' deficit, Nasdaq non-compliance, and a 'going concern' warning. While there are positive clinical trial results for lead candidates, the immediate financial instability and high dilution risk overshadow these developments, indicating a precarious situation for investors.

Positives

• Mipletamig, a lead clinical candidate for AML, shows promising initial results in the RAINIER trial, with 5 out of 6 evaluable patients achieving remission, including one with complete remission and no minimal residual disease (MDR-negative).
• All patients in the RAINIER trial achieved remission within 30 days of treatment initiation.
• Across two trials, 9 out of 10 frontline AML patients achieved complete remission or complete remission with blood markers not yet recovered when receiving the triplet combination of mipletamig + venetoclax + azacitidine.
• ALG.APV-527, a lead solid tumor candidate, demonstrated positive safety and tolerability with no liver toxicity, a common side effect for similar treatments, and 58% of patients achieving stable disease in preliminary results.
• The company possesses two versatile and wholly-owned platform technologies, ADAPTIR and ADAPTIR-FLEX, enabling efficient design of novel bispecific and multi-specific immunotherapeutic candidates.
• A provisional patent for preclinical candidate APVO711 was filed in January 2023 and amended in January 2024, indicating ongoing innovation and intellectual property development.

Negatives

• The company reported a net loss of $(6.408) million for the three months ended March 31, 2025, and a net loss of $(24.130) million for the year ended December 31, 2024, indicating continued unprofitability.
• As of March 31, 2025, the company had a shareholders' deficit of approximately $(1.473) million, falling below Nasdaq's minimum $2.5 million shareholders' equity requirement.
• The company received a Nasdaq notification on May 17, 2025, regarding non-compliance with the minimum shareholders' equity requirement, with a deadline of July 7, 2025, to submit a compliance plan.
• The company's recent 1-for-20 reverse stock split on May 23, 2025, means it is not eligible for a 180-day cure period for Nasdaq's $1.00 minimum bid price requirement, risking immediate delisting if the price drops below this threshold.
• The offering is on a 'reasonable best efforts' basis with no minimum amount of securities required to be sold, meaning the company may not raise sufficient capital to adequately fund its intended uses of proceeds.
• The offering will result in immediate and substantial dilution to existing stockholders, with a dilution of $2.97 per share to new investors based on the assumed offering price.
• There is no established public trading market for the common or pre-funded warrants, and the company does not expect one to develop, limiting their liquidity.
• The common warrants are not exercisable without Stockholder Approval, which is not guaranteed and may incur substantial costs and management time to obtain.
• The company has been and may in the future be subject to short selling strategies that could drive down the market price of its common stock.
• The Securities Purchase Agreement does not prohibit short sales between the closing of the offering and obtaining Stockholder Approval, which could negatively impact the stock price.

Risks

• The company has broad discretion in the use of net proceeds from the offering and may not use them effectively, potentially leading to financial losses and delayed product development.
• Purchasers will experience immediate and substantial dilution in the net tangible book value per share of common stock, and future equity offerings could cause further dilution.
• There is no public market for the common warrants or pre-funded warrants, and no market is expected to develop, limiting their liquidity.
• The common warrants are not exercisable until Stockholder Approval is obtained, which is not guaranteed, and if not obtained, the warrants will have no value.
• The company may incur substantial costs and management time in attempting to obtain Stockholder Approval for the common warrants.
• The company has been and may in the future be subject to short selling strategies that could drive down the market price of its common stock.
• The Securities Purchase Agreement does not prohibit short sales between the time of closing and obtaining Stockholder Approval, which may cause substantial short selling activity and stock price decline/volatility.
• The common warrants and pre-funded warrants are speculative in nature and may not become profitable to exercise.
• As a 'reasonable best efforts' offering with no minimum, the company may not raise sufficient capital for its business plans, potentially requiring additional, possibly unfavorable, financing.
• Purchasers who enter into a securities purchase agreement may have rights superior to those who do not.
• Resales of common stock by existing stockholders during the offering period may depress the market price.
• The offering itself may cause the trading price of the common stock to decrease.
• The company is at risk of delisting from the Nasdaq Capital Market due to non-compliance with the minimum shareholders' equity requirement ($1.473 million deficit vs. $2.5 million minimum).
• Due to a recent reverse stock split, the company is not eligible for a 180-day cure period for the Nasdaq $1.00 minimum bid price requirement, risking immediate delisting if the price falls below this.
• If delisted from Nasdaq, the common stock may become subject to 'penny stock' rules, making it difficult to trade and adversely affecting liquidity and market price.

Future Outlook

Aptevo Therapeutics aims to advance its lead clinical candidates, mipletamig and ALG.APV-527, through further clinical development, including the ongoing RAINIER trial for AML and continued investigation for solid tumors. The company also plans to continue developing its preclinical candidates (APVO603, APVO442, APVO711) and expand its pipeline by generating novel bispecific and multi-specific proteins using its ADAPTIR and ADAPTIR-FLEX platforms. Strategic collaborative partnerships are also a key part of the future strategy to broaden the pipeline and secure funding for R&D. The company expects to continue to expand its product pipelines to address areas of unmet medical need.

Management Comments

• "We believe our candidates in development and our future molecules derived from our ADAPTIR and ADAPTIR-FLEX platforms will be highly competitive in the market as they are rationally designed for safety and tolerability as well as efficacy."

Industry Context

The biotechnology industry, particularly in oncology, is seeing increasing recognition of bispecific therapeutics as potent anti-cancer agents. Sixteen new bispecific agents have been approved by the FDA in the last three years, with a total of 125 bispecific drug candidates currently in development. Aptevo's focus on its ADAPTIR and ADAPTIR-FLEX platforms positions it within this growing segment, aiming to develop novel immunotherapies with structural and functional advantages over traditional monoclonal antibodies. The company's strategy to pursue collaborations aligns with common industry practices for funding R&D and expanding product portfolios in capital-intensive drug development.

Comparison to Industry Standards

• Aptevo's mipletamig, a CD3xCD123 T cell engager, is being clinically evaluated in the RAINIER trial for frontline acute myelogenous leukemia (AML) in combination with standard of care venetoclax + azacitidine. This combination therapy approach is common in oncology to enhance efficacy and overcome resistance, similar to strategies employed by companies developing novel AML treatments.
• ALG.APV-527 targets 4-1BB (co-stimulatory receptor) and 5T4 (tumor antigen). The document highlights that 4-1BB can stimulate immune cells involved in tumor control, making it a compelling target. This aligns with broader industry trends in immuno-oncology focusing on co-stimulatory pathways, similar to approaches by companies like Bristol Myers Squibb (with Opdivo/Yervoy combinations) or other biotechs developing next-generation T-cell engagers and immune checkpoint modulators.
• The company's ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates. The document notes that 16 new bispecific agents have been FDA-approved in the last three years, and 125 bispecific drug candidates are in development. This indicates a robust and competitive market, with companies like Amgen (e.g., Blincyto) and Roche (e.g., Lunsumio) having established bispecific antibody platforms and approved products. Aptevo aims to compete by designing molecules for improved safety, tolerability, and efficacy.
• The company's financial position, specifically its shareholders' deficit of $(1.473) million as of March 31, 2025, and the Nasdaq non-compliance notice, indicates a financial health below typical industry standards for publicly traded biotechnology companies, which often require substantial capital to fund lengthy and expensive drug development cycles. Many established biotech companies maintain positive shareholders' equity and robust cash reserves to support their pipelines.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Existing shareholders will experience immediate and substantial dilution due to the offering. The risk of Nasdaq delisting could further reduce liquidity and market price. The Shareholder Rights Plan aims to protect against hostile takeovers but may also limit potential acquisition premiums.
• **New Investors**: New investors will face immediate dilution and the speculative nature of the warrants, which may not become exercisable without stockholder approval. The 'reasonable best efforts' nature of the offering means the company may not raise sufficient capital, impacting its ability to execute plans.
• **Employees**: Continued operations and product development depend on successful capital raises. Financial instability and delisting risks could impact employee morale, retention, and the value of equity-based compensation.
• **Customers/Patients**: The successful development of product candidates like mipletamig and ALG.APV-527 could offer new treatment options for cancer patients, but the company's financial challenges pose a risk to the continuity and advancement of these programs.
• **Creditors**: The company's 'going concern' uncertainty and shareholders' deficit indicate a heightened risk for creditors, as the company's ability to meet its financial obligations is in question without additional funding.

Next Steps

• The company will file a Current Report on Form 8-K, including the Transaction Documents as exhibits, with the Commission within the time required by the Exchange Act.
• The company will apply to list or quote all of the Shares and Warrant Shares on the Nasdaq Capital Market and promptly secure their listing.
• The company will hold a special meeting of stockholders within 60 days after the Closing Date to obtain Stockholder Approval for the exercise of the Common Warrants.
• If Stockholder Approval is not obtained at the first meeting, the company will call a meeting every 60 days thereafter until approval is secured or the warrants are no longer outstanding.
• The company will submit a plan to Nasdaq by July 7, 2025, to regain compliance with the minimum shareholders' equity requirement.
• The company will continue to advance its lead clinical blood cancer candidate, mipletamig, through clinical development, including the ongoing RAINIER trial.
• The company will continue advancing its lead solid tumor candidate, ALG.APV-527, in the clinic.
• The company will continue development and advancement of its preclinical candidates: APVO603, APVO442, and APVO711, through preclinical and IND-enabling studies.
• The company plans to generate additional novel bispecific and multi-specific protein immunotherapies using its ADAPTIR and ADAPTIR-FLEX platforms.
• The company intends to pursue collaborative partnerships to broaden its pipeline and provide funding for research and development.

Key Dates

Recommendation

Keywords

Biotechnology, Immunotherapy, Cancer, Oncology, AML, Solid Tumors, Bispecific Antibodies, ADAPTIR, ADAPTIR-FLEX, Mipletamig, ALG.APV-527, Preclinical Development, Clinical Trials, SEC Filing, S-1, Public Offering, Common Stock, Warrants, Pre-funded Warrants, Capital Raise, Dilution, Nasdaq Listing, Shareholders' Equity, Risk Factors, Corporate Governance, APVO